Aim: To investigate the relationship between the onsets of multikinase inhibitor (MKI)-associated hand-foot skin reaction (HFSR) and prognosis under intervention by pharmacists after the introduction of sorafenib.

Methods: We conducted a retrospective study involving 40 patients treated with sorafenib. Intervention by pharmacists began at the time of treatment introduction and continued until the appearance of symptomatic exacerbation or non-permissible adverse reactions. We examined the relationship between MKI-associated HFSR and overall survival (OS) after the initiation of treatment.

Results: The median OS was 10.9 mo in the MKI-associated HFSR group and 3.4 mo in the no HFSR group, showing a significant difference in multivariate analysis. A multivariate analysis of the time to treatment failure indicated that the intervention by pharmacists and MKI-associated HFSR were significant factors. The median cumulative dose and the mean medication possession ratio were significantly higher in the intervention group than in the non-intervention group. A borderline significant difference was observed in terms of OS in this group.

Conclusion: Intervention by pharmacists increased drug adherence. Under increased adherence, MKI-associated HFSR was an advantageous surrogate marker. Intervention by healthcare providers needs to be performed for adequate sorafenib treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064964PMC
http://dx.doi.org/10.3748/wjg.v24.i28.3155DOI Listing

Publication Analysis

Top Keywords

intervention pharmacists
16
mki-associated hfsr
16
hand-foot skin
8
skin reaction
8
treated sorafenib
8
time treatment
8
hfsr group
8
multivariate analysis
8
hfsr
6
intervention
6

Similar Publications

Background: The pharmacy profession must address climate change and its impact on health. Student pharmacists should be made aware of roles in sustainability, education, patient care, and advocacy; yet, pharmacy educators' perceptions of climate change and health may impact the extent and quality of education provided.

Objective: The primary objective was to assess pharmacy educators' beliefs regarding climate change and whether its effects on health should be included in Doctor of Pharmacy curricula.

View Article and Find Full Text PDF

Background: Hypertension is a major contributor to global cardiovascular morbidity and mortality. Treatment-resistant hypertension (TRH) presents a significant management challenge, requiring a pharmacist-physician collaborative model to achieve sustained blood pressure (BP) control.

Aim: This study aims to evaluate the impact of a clinical pharmacy interventions on BP control, medication adherence, and patient outcomes in patients with TRH in a primary care setting.

View Article and Find Full Text PDF

The Australian Government has enacted laws restricting the supply of electronic cigarettes (vapes) to people requiring them for smoking cessation or the treatment of nicotine dependence, under the care of a medical practitioner, nurse practitioner or pharmacist. Currently no vapes are included on the Australian Register of Therapeutic Goods, meaning that the prescription and supply of therapeutic vapes must be through the Special Access Scheme or Authorised Prescriber pathways. Clinical guidelines state that therapeutic vapes may be considered for supporting people who have been unable to quit smoking using first-line therapies (a combination of behavioural support and registered nicotine replacement therapies or oral smoking cessation medicines).

View Article and Find Full Text PDF

Background: Medication safety is crucial in clinical care. Although many hospitals have implemented prospective prescription review systems to manage medication use, the impact of these systems on pediatric patients is not yet fully understood.

Objectives: We explore the characteristics and economic impacts of pediatric prospective prescription review and identify factors influencing intervention success rates.

View Article and Find Full Text PDF

Contingency management (CM), an evidence-based behavioral strategy that rewards positive behavior change including tobacco cessation, is rarely offered to support people with HIV (PWH) who smoke. In this study, we explored perspectives among patients and research staff engaged in a multi-site randomized clinical trial involving clinical pharmacist-delivered CM within HIV clinics. Between February and September 2023, we conducted 1:1 interviews with 12 PWH randomized to receive CM and one focus group with 8 staff (i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!